

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	HeraMED Limited
ABN	65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Groberman
Date of appointment	25 September 2018

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>Altshuler Shaham Trusts Ltd <David Groberman A/C> (beneficial holder)</p>	<p>7,995,723 Ordinary fully paid ordinary shares escrowed 24 months from quotation</p> <p>3,187,500 Unlisted options @ \$0.25 expiring 5/12/21 escrowed 24 months from quotation</p> <p>463,752 Unlisted options @ \$0.00002 expiring 5/12/21 escrowed 24 months from quotation</p>

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Share swap agreement dated on or about 26 June 2018 between the Company, Hera-Med Ltd (Registration No. P.C 51-467654-3) (HeraMED Israel) and the shareholders of HeraMED Israel (Vendors) as amended on 19 November 2018 (Acquisition Agreement).
Nature of interest	<p>Entitlement to be issued fully paid ordinary shares (Deferred Consideration Shares) as a Vendor pursuant to the Acquisition Agreement if performance milestones are satisfied.</p> <p>(i) Milestone One: The Company receiving FDA approval for HeraBEAT to be used as a clinical medical device in the US on or before the date that is 12 months from 12 December 2018.</p> <p>(ii) Milestone Two: The Company reaching cumulative revenue of AUD7.5 million which shall be verified by an independent auditor's report within 24 months of 12 December 2018.</p> <p>(iii) Milestone Three: The Company reaching cumulative revenue of AUD15 million which shall be verified by an independent auditor's report within 36 months of 12 December 2018.</p>
Name of registered holder (if issued securities)	Not applicable. No Deferred Consideration Shares have yet been issued.

+ See chapter 19 for defined terms.

Appendix 3X
Initial Director's Interest Notice

No. and class of securities to which interest relates	(i) Milestone One: 1,249,695 ordinary shares fully paid (ii) Milestone Two 1,249,695 fully paid ordinary shares (iii) Milestone Three: 1,922,608 fully paid ordinary shares
--	---

+ See chapter 19 for defined terms.